Advertisement

Journal of Molecular Neuroscience

, Volume 34, Issue 1, pp 45–50 | Cite as

ApoE Distribution and Family History in Genetic Prion Diseases in Germany

  • Anna Krasnianski
  • Nicolas von Ahsen
  • Uta Heinemann
  • Bettina Meissner
  • Hans A. Kretzschmar
  • Victor W. Armstrong
  • Inga Zerr
Article

Abstract

We analyzed the ApoE genotype in patients with genetic prion diseases (gPD) with respect to family history (FH) of dementia/prion disease (PD) compared to non-demented controls. Fifty-nine gPD patients and 51 sex-/age-matched controls were included. A positive FH of dementia and PD (PFH) were evaluated. The prion protein gene (PRNP) codon 129 and ApoE genotype were determined by polymerase chain reaction (PCR). The frequency of FH of neurodegenerative disorder/prion disease/dementia varied in different PRNP mutations. PFH was found in 87% of D178N patients, but was rarer in others. Although the ApoE genotype distribution was not significantly different between gPD patients and controls, the protective E2 alleles were more frequent in controls than in patients without a PFH and even less frequent in those with a PFH (18, 16, and 11%). E4 alleles as a risk factor of Alzheimer’s disease were more common in controls and patients with a PFH than in those without PFH (25, 21, and 13%). No effect of the codon 129 genotype was detected. Only about two-thirds of gPD patients had PFH of PD, while in one-third, PFH of slowly progressive dementia was reported. Underreporting of PFH of gPD may play a role; however, the varying PFH frequency across various mutations is not explained by this factor only.

Keywords

ApoE CJD Codon 129 genotype PRNP Dementia 

Notes

Acknowledgement

We thank Ms. Bodemer, Ms. Ciesielczyk, Ms. Hartung, Ms. Henn, and Ms. Staniszewski for technical assistance. The assistance of Ms. Ehrlich is gratefully acknowledged. This study was supported by grants from the Federal Ministry of Health and Social Security (325-4471-02/15), the European Commission (QLG3-CT-2002-81606), and the Federal Ministry of Education and Research (01GI0301).

References

  1. Alpérovitch, A., Zerr, I., Pocchiari, M., et al. (1999). Codon 129 prion protein genotype and sporadic Creutzfeldt–Jakob disease. Lancet, 353, 1673–1674.PubMedCrossRefGoogle Scholar
  2. Amouyel, P., Vidal, O., Launay, J. M., & Laplanche, J. L. (1994). The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt–Jakob disease. The French research group on epidemiology of human spongiform encephalopathies. Lancet, 344, 1315–1318.PubMedCrossRefGoogle Scholar
  3. Chapman, J., Cervenakova, L., Petersen, R. B., et al. (1998). APOE in non-Alzheimer amyloidoses: Transmissible spongiform encephalopathies. Neurology, 51, 548–553.PubMedGoogle Scholar
  4. Corder, E. H., Saunders, A. M., Risch, N. J., et al. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics, 7, 180–184.PubMedCrossRefGoogle Scholar
  5. Corder, E. H., Saunders, A. M., Strittmatter, W. J., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261, 921–923.PubMedCrossRefGoogle Scholar
  6. Davidson, Y., Gibbons, L., Purandare, N., et al. (2006). Apolipoprotein E epsilon4 allele frequency in vascular dementia. Dementia and Geriatric Cognitive Disorders, 22, 15–19.PubMedCrossRefGoogle Scholar
  7. Del Bo, R., Scarlato, M., Ghezzi, S., et al. (2006). Is M129V of PRNP gene associated with Alzheimer’s disease? A case-control study and a meta-analysis. Neurobiology of Aging, 27, 770.e1–770.e5.CrossRefGoogle Scholar
  8. Gerdes, L. U., Klausen, I. C., Sihm, I., & Faergeman, O. (1992). Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genetic Epidemiology, 9, 155–167.PubMedCrossRefGoogle Scholar
  9. Goldfarb, L. G., Brown, P., & Gajdusek, D. C. (1992).The molecular genetics of human transmissible spongiform encephalopathy. In S. B. Prusiner, J. Collinge, J. Powell, & B. Anderton (Ed.), Prion diseases of human and animals (pp. 139–153).Google Scholar
  10. Huang, Y. (2006). Apolipoprotein E and Alzheimer disease. Neurology, 66, S79–S85.PubMedCrossRefGoogle Scholar
  11. Kitamoto, T, Shin, R. W., Doh-Ura, K., et al. (1992). Abnormal isoform of prion proteins accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt–Jakob disease. American Journal of Pathology, 140, 1285–1294.PubMedGoogle Scholar
  12. Kovacs, G. G., Puopolo, M., Ladogana, A., et al. (2005). Genetic prion disease: the EUROCJD experience. Human Genetics, 118, 166–174.PubMedCrossRefGoogle Scholar
  13. Kovács, G. G., Trabattoni, G., Hainfellner, J. A., Ironside, J. W., Knight, R. S., & Budka, H. (2002). Mutations of the prion protein gene. Phenotypic spectrum. Journal of Neurology, 249, 1567–1582.PubMedCrossRefGoogle Scholar
  14. Kretzschmar, H. A., Ironside, J. W., DeArmond, S. J., & Tateishi, J. (1996). Diagnostic criteria for sporadic Creutzfeldt–Jakob disease. Archives of Neurology, 53, 913–920.PubMedGoogle Scholar
  15. Ladogana, A., Puopolo, M., Croes, E. A., et al. (2005). Mortality from Creutzfeldt–Jakob disease and related disorders in Europe, Australia, and Canada. Neurology, 64, 1586–1591.PubMedCrossRefGoogle Scholar
  16. Mastrianni, J. A., Iannicola, C., Myers, R. M., DeArmond, S., & Prusiner, S. B. (1996). Mutation of the prion protein gene at codon 208 in familial Creutzfeldt–Jakob disease. Neurology, 47, 1305–1312.PubMedGoogle Scholar
  17. Mollenhauer, B., Trenkwalder, C., von Ahsen, N., et al. (2006) Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia. Dementia and Geriatric Disorders, 22, 200–208.CrossRefGoogle Scholar
  18. Nakagawa, Y., Kitamoto, T., Furukawa, H., Ogomori, K., & Tateishi, J. (1995). Allelic variation of apolipoprotein E in Japanese sporadic Creutzfeldt–Jakob disease patients. Neuroscience Letters, 187, 209–211.PubMedCrossRefGoogle Scholar
  19. O’Brien, J., Ames, D., & Burns, A. (2000). Dementia. London: Arnold.Google Scholar
  20. Palmer, M. S., Dryden, A. J., Hughes, J. T., & Collinge, J. (1991). Homozygous prion protein genotype predisposes to sporadic Creutzfeldt–Jakob disease [published erratum appears in Nature 1991 Aug 8;352(6335):547] [see comments]. Nature, 352, 340–342.PubMedCrossRefGoogle Scholar
  21. Raymond, M., & Rousset, F. (1995). Population genetics software for exact tests and ecumenicism. Journal of Heredity, 86, 248–249.Google Scholar
  22. Salvatore, M., Seeber, A. C., Nacmias, B., et al. (1995). Apolipoprotein E in sporadic and familial Creutzfeldt–Jakob disease. Neuroscience Letters, 199, 95–98.PubMedCrossRefGoogle Scholar
  23. Saunders, A. M., Schmader, K., Breitner, J. C., et al. (1993). Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases [see comments]. Lancet, 342, 710–711.PubMedCrossRefGoogle Scholar
  24. Schulz-Schaeffer, W. J., Tschoke, S., Kranefuss, N., et al. (2000). The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases. American Journal of Pathology, 156, 51–56.PubMedGoogle Scholar
  25. Van Everbroeck, B., Green, A., Pals, P., Martin, J. J., & Cras, P. (1999). Decreased levels of amyloid-beta 1-42 in cerebrospinal fluid of Creutzfeldt–Jakob disease patients. Journal of Alzheimers Disease, 1, 419–424.Google Scholar
  26. WHO (1998). Human transmissible spongiform encephalopathies. Weekly Epidemiological Record, 47, 361–365.Google Scholar
  27. Zannis, V. I., Just, P. W., & Breslow, J. L. (1981). Human apolipoprotein E isoprotein subclasses are genetically determined. American Journal of Human Genetics, 33, 11–24.PubMedGoogle Scholar
  28. Zarranz, J. J., Digon, A., Atares, B., et al. (2005). Phenotypic variability in familial prion diseases due to the D178N mutation. Journal of Neurology, Neurosurgery and Psychiatry, 76, 1491–1496.CrossRefGoogle Scholar
  29. Zerr, I., Helmhold, M., Poser, S., Armstrong, V. W., & Weber, T. (1996). Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt–Jakob disease. Archives of Neurology, 53, 1233–1238.PubMedGoogle Scholar
  30. Zerr, I., Pocchiari, M., Collins, S., et al. (2000). Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease. Neurology, 55, 811–815.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Anna Krasnianski
    • 1
  • Nicolas von Ahsen
    • 2
  • Uta Heinemann
    • 1
  • Bettina Meissner
    • 1
  • Hans A. Kretzschmar
    • 3
  • Victor W. Armstrong
    • 2
  • Inga Zerr
    • 1
  1. 1.National Reference Center for TSE Surveillance, Department of NeurologyGeorg-August University GöttingenGöttingenGermany
  2. 2.Department of Clinical ChemistryGeorg-August University GöttingenGöttingenGermany
  3. 3.Department of NeuropathologyLudwig-Maximilian UniversityMunichGermany

Personalised recommendations